Navigation Links
Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
Date:12/21/2011

injection of JX-594 intravenously or intratumorally two weeks prior to surgical resection. Tumors will be evaluated for evidence of JX-594 replication and pathologic response. Patients will subsequently be followed for progression-free survival and overall survival. For more information about the trial, please visit www.clinicaltrials.gov.

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis and is well-tolerated by patients (over 120 treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. JX-594 has had a favorable safety profile to date with predictable and generally mild side effects that typically include flu-like symptoms that resolve in 24 to 48 hours.

JX-594 is the most advanced product candidate from Jennerex's proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform.  SOLVE takes advantage of the natural attributes of poxviruses as well as their ability to be genetically engineered to produce safe, therapeutic viruses that can infect solid tumors both systemically and locally.  The vaccinia poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targe
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... ALEXANDRIA, Va. and WASHINGTON ... of Specialty Pharmacy (NASP) and SmartBrief recently partnered to ... with a snapshot of the top news in the ... specialty pharmacies, pharmaceutical and biotechnology manufacturers, GPOs, distributors and ... free resource will launch on April 27, 2015. ...
(Date:4/27/2015)... -- The North America ... $4,211.2 million by 2019, at a CAGR of 5.0% from ... the North America ophthalmology surgery device ... It also provides a glimpse of the segmentation of this ... tables and figures. http://www.micromarketmonitor.com/market/north-america-ophthalmology-surgery-devices-9102894245.html ...
(Date:4/27/2015)... The North America ... and geography and includes analysis and forecast of revenue. This ... expected to reach $829.9 million by 2019, at a CAGR ... the TOC of the North America Optical microscopy market report, ... also provides a glimpse of the segmentation in this market, ...
Breaking Medicine Technology:NASP and SmartBrief Partner on Specialty Pharmacy SmartBrief 2North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 2North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 3North America Optical Microscopy Market is Expected to Reach $829.9 Million by 2019, at a CAGR of 3.0% From 2014 to 2019 2North America Optical Microscopy Market is Expected to Reach $829.9 Million by 2019, at a CAGR of 3.0% From 2014 to 2019 3
... Necessary For Diabetic Patients, BOSTON, Sept. 13 ... the United States alone. Coronary artery,disease (CAD) is a ... ischemia is common, and cardiac death or myocardial,infarction may ... the Detection of Ischemia in Asymptomatic Diabetics (DIAD),Study, presented ...
... Australia, Sept. 12 Sunshine Heart (ASX: SHC),a ... assist,technologies, today announced that it has received conditional ... U.S. Food and Drug,Administration (FDA) to begin its ... in patients with moderate heart failure. C-Pulse is,an ...
Cached Medicine Technology:Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study 2Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial 2Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial 3
(Date:4/28/2015)... Colorado spine surgeon Donald Corenman, MD, ... popular spine education website NECKANDBACK.COM and his ... Media. This website has been redesigned to help patients ... spine, causes of neck and back pain, and conditions ... and personally answers questions in the neck and back ...
(Date:4/28/2015)... The buyer power score for ... indicating a medium level of buyer power in the ... equal power during negotiations. One factor helping buyer power ... health insurance policy from an insurance carrier (such as ... choose to self-fund their own policy or forgo insurance ...
(Date:4/28/2015)... It’s not all about the law at the Law ... litigation and plaintiff’s personal injury lawyer that has also served ... also about giving back to the community. This is ... Research Center Innovator’s Network. , “I believe there is a ... can and do good community-focused work in their communities,” said ...
(Date:4/28/2015)... SeniorCare.com has published the Misconception ... problem Americans have regarding aging and long-term care needs. ... services as they age, 63% of Americans do NOT ... the report, Carol Marak of SeniorCare.com interviewed 44 senior ... Care Association and The Scan Foundation. The experts discuss ...
(Date:4/28/2015)... Dead or damaged trees can quickly turn into ... cases, tree removal by a skilled team is recommended as ... , In their latest article , Precision Tree ... property owners today. Each method requires skill and expertise that ... , The article states that, “Tree removal is not “one ...
Breaking Medicine News(10 mins):Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 2Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:Seattle Attorney Paul Schneiderman Helping to Combat Cancer 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Tree Removal Methods and Services Discussed in Recent Article by Precision Tree Services 2
... Jan. 28 Prime Companies, Inc. (Pink Sheets: PCIR) ... that will allow it to spin off its wholly ... 2007, to a San Diego firm which, once it ... 15 percent of the new company.The agreement with TransPacific ...
... Essential Hospital Guide to Get Your Loved One Out Alive," by ... Health Book of the Year by Allbooks Review Editor,s Choice Awards ... ... 2009 -- "Critical Conditions: The Essential Hospital Guide to Get Your ...
... of Health Strategies & Solutions, Inc the largest healthcare consultant in ... her expertise in management, governance, finance, operations and medical staff. ... ... The nation,s leading healthcare consulting firm, Health Strategies & ...
... A University of Rochester Medical Center study challenges common assumptions ... some people, surprisingly high levels remain in the body even ... suggests that BPA exposure may come from non-food sources, or ... journal Environmental Health Perspectives published the research online ...
... Jan. 27 Minnesotans with chronic,conditions and disabilities ... under the proposed budget of Gov. Tim Pawlenty, ... Center. , "As a ... thousands of Minnesotans following an illness, surgery or ...
... officials say company distributed ,adulterated, peanut butter products in ... -- The Georgia facility that produced the peanut butter ... in the past distributed questionable peanut butter product, U.S. ... 2008, Peanut Corporation of America, which owns the now-closed ...
Cached Medicine News:Health News:Prime Companies Reaches Agreement to Spin Off Subsidiary; Shareholders Gain 15 Percent Stake in New Telecommunications Company 2Health News:"Critical Conditions" Wins Best Health Book of the Year Awards 2Health News:New Employee of the Nations Largest Healthcare Consulting Firm 2Health News:Rochester study raises new questions about controversial plastics chemical 2Health News:Rochester study raises new questions about controversial plastics chemical 3Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 2Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 3Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
VascoStim 2F are bipolar temporary pacing leads to be used in conjunction with thermodilution catheters with implemented paceport-channel....
Unipolar Ventricular Lead...
The Guidant Fineline leads are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing....
Medicine Products: